Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.30 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.30 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239510 | 1.00 | ADRB1 (0.31) | ADRB1ADRB3ADRB2KCNA5KCNJ5 | |
| SCHEMBL1841859 | 0.93 | KCNA5 (0.36) | ADRB1ADRB3ADRB2KCNA5KCNJ5 | |
| SCHEMBL2080830 | 0.93 | KCNA5 (0.36) | ADRB1ADRB3ADRB2KCNA5KCNJ5 | |
| SCHEMBL4250387 | 0.87 | ADRB3 (0.33) | ADRB1ADRB3ADRB2 | |
| SCHEMBL12662932 | 0.81 | KCNA5 (0.34) | KCNA5KCNJ5KCNJ3SCN5AKCND3 | |
| SCHEMBL4250379 | 0.81 | KDM4E (0.33) | — | |
| SCHEMBL4250383 | 0.81 | KDM4E (0.33) | — | |
| SCHEMBL4247239 | 0.76 | ADRB3 (0.31) | ADRB1ADRB3ADRB2 | |
| SCHEMBL4247242 | 0.76 | ADRB3 (0.31) | ADRB1ADRB3ADRB2 | |
| SCHEMBL14149054 | 0.76 | KCNA5 (0.34) | KCNA5KCNJ5KCNJ3SCN5AKCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| EP-1758862-A1 | AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS | Pfizer Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005115985-A1 | AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS | PFIZER LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | DRD2, DRD1, DRD3 | ADRB1 34/4885ADRB3 14/4885ADRB2 22/4885 |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | DRD2, DRD1, DRD3 | ADRB1 54/4885ADRB3 23/4885ADRB2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.